Phosphonic Acid

Phosphonic Acid

SCHEMBL5696293

CCCCC(CC)CCCC(CC)CCCC.O=[PH](O)O.O=[PH](O)O

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.56
CA2 P00918 6/20 0.55
TDP1 Q9NUW8 2/20 0.50
CYP3A4 P08684 5/20 0.48
TSHR P16473 4/20 0.48
ATM Q13315 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
MAPK1 P28482 1/20 0.41
CA1 P00915 1/20 0.40
LMNA P02545 1/20 0.39
MMP9 P14780 1/20 0.39
MMP8 P22894 1/20 0.39
MMP14 P50281 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphonic Acid SCHEMBL11044392 0.93 ALDH1A1 (0.58) ALDH1A1CA2TDP1CYP3A4TSHR
Phosphonic Acid SCHEMBL11040987 0.87 ALDH1A1 (0.50) ALDH1A1CA2TDP1CYP3A4TSHR
Phosphonic Acid SCHEMBL20723523 0.86 ALDH1A1 (0.78) ALDH1A1CA2TDP1CYP3A4TSHR
Phosphonic Acid SCHEMBL11042967 0.86 ALDH1A1 (0.50) ALDH1A1CA2TDP1CYP3A4TSHR
Phosphonic Acid SCHEMBL28608610 0.85 ALDH1A1 (0.50) ALDH1A1CA2TDP1CYP3A4TSHR
SCHEMBL4653062 0.84 ALDH1A1 (0.65) ALDH1A1CA2TDP1CYP3A4TSHR
Phosphonic Acid SCHEMBL9262594 0.84 LMNA (0.54) ALDH1A1CA2TDP1CYP3A4TSHR
Phosphonic Acid SCHEMBL11880909 0.84 LMNA (0.54) ALDH1A1CA2TDP1CYP3A4TSHR
Phosphonic Acid SCHEMBL28813732 0.84 LMNA (0.54) ALDH1A1CA2TDP1CYP3A4TSHR
Phosphonic Acid SCHEMBL2401623 0.84 LMNA (0.54) ALDH1A1CA2TDP1CYP3A4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030206857-A1 Produce radium-223 by loading a mother nuclide on generator column containing Ac-resin on an inorganic matrix, or comprising a step using AC-resin in a liquid/liquid extraction system. ALGETA AS (NO) 2003-11-06 US claimed
EP-1140212-B1 THE USE OF RADIUM-223 TO TARGET CALCIFIED TISSUES FOR PAIN PALLIATION AND THERAPY OF BONE CANCER ALGETA AS (NO) 2006-06-28 EP disclosed
US-20030206857-A1 Produce radium-223 by loading a mother nuclide on generator column containing Ac-resin on an inorganic matrix, or comprising a step using AC-resin in a liquid/liquid extraction system. ALGETA AS (NO) 2003-11-06 US disclosed
US-6635234-B1 Administering bone seeking alpha-emitting radionuclide having half-life allowing deeper incorporation into matrix of bone surfaces before decay and radioactive decay products from its transformation do not translocalize significantly ANTICANCER THERAPEUTIC INVENTIONS AS (NO) 2003-10-21 US disclosed